HOXB4 knockdown reverses multidrug resistance of human myelogenous leukemia K562/ADM cells by downregulating P-gp, MRP1 and BCRP expression via PI3K/Akt signaling pathway
Authors:
- 18 October 2016
- journal article
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 49 (6) , 2529-2537
Abstract
Spandidos Publications is a scientific publisher with a long-standing international reputation for excellent standards and high quality science publicationsKeywords
This publication has 37 references indexed in Scilit:
- Early switch in tyrosine kinase inhibitor therapy for patients with chronic myeloid leukemia: An emerging clinical questionCritical Reviews in Oncology/Hematology, 2016
- Discovery of 2-Acylaminothiophene-3-Carboxamides as Multitarget Inhibitors for BCR-ABL Kinase and MicrotubulesJournal of Chemical Information and Modeling, 2015
- A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinibTumor Biology, 2015
- Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patientsAnnals of Hematology, 2015
- Wnt/β-catenin pathway regulates ABCB1 transcription in chronic myeloid leukemiaBMC Cancer, 2012
- Mutant BCR-ABL clones in chronic myeloid leukemiaHaematologica, 2011
- Bcr–Abl-independent mechanism of resistance to imatinib in K562 cells: Induction of cyclooxygenase-2 (COX-2) by histone deacetylases (HDACs)Leukemia Research, 2010
- AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based ResistanceCancer Cell, 2009
- P-glycoprotein: from genomics to mechanismOncogene, 2003
- Mechanisms of Cancer Drug ResistanceAnnual Review of Medicine, 2002